Cullen Capital Management LLC Purchases New Holdings in Zoetis Inc. $ZTS

Cullen Capital Management LLC purchased a new position in shares of Zoetis Inc. (NYSE:ZTS) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 11,152 shares of the company’s stock, valued at approximately $801,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. RFG Advisory LLC grew its holdings in shares of Zoetis by 4.9% during the 4th quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock worth $215,000 after purchasing an additional 80 shares in the last quarter. Financial Engines Advisors L.L.C. increased its position in shares of Zoetis by 4.4% in the third quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company’s stock worth $299,000 after purchasing an additional 87 shares during the period. Physician Wealth Advisors Inc. raised its stake in Zoetis by 17.4% in the first quarter. Physician Wealth Advisors Inc. now owns 615 shares of the company’s stock valued at $73,000 after purchasing an additional 91 shares in the last quarter. Smithfield Trust Co raised its stake in Zoetis by 4.2% in the fourth quarter. Smithfield Trust Co now owns 2,294 shares of the company’s stock valued at $290,000 after purchasing an additional 92 shares in the last quarter. Finally, Howland Capital Management LLC lifted its position in Zoetis by 4.5% during the second quarter. Howland Capital Management LLC now owns 2,137 shares of the company’s stock worth $333,000 after purchasing an additional 92 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $77.13 on Tuesday. Zoetis Inc. has a one year low of $71.00 and a one year high of $157.21. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. The company has a market cap of $31.87 billion, a price-to-earnings ratio of 12.71, a PEG ratio of 1.82 and a beta of 0.73. The firm has a 50 day simple moving average of $75.70 and a 200 day simple moving average of $96.81.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. The firm had revenue of $2.47 billion for the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company’s revenue was down .2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Research analysts predict that Zoetis Inc. will post 6.2 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on ZTS shares. Morgan Stanley set a $85.00 price target on shares of Zoetis in a report on Friday, August 7th. Weiss Ratings cut shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 12th. UBS Group cut their target price on Zoetis from $85.00 to $80.00 and set a “neutral” rating for the company in a research note on Friday, August 7th. Zacks Research downgraded Zoetis from a “hold” rating to a “strong sell” rating in a report on Monday, August 10th. Finally, Argus reiterated a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Eight investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Zoetis currently has an average rating of “Hold” and an average price target of $109.23.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.